Objective  To analyze the rules and characteristics of cross-allergy cases related to drug-related medical disputes, and to provide reference for the formulation of cross-allergy prescription review strategy.

Methods  The judgments of cross-allergy related medical damage liability disputes recorded in the legal document database of Beijing Yingke Law Firm and the Chinese Judgment Document Network database from August 2010 to June 2023 were analyzed, the causes of relevant disputes were summarized and analyzed, and more comprehensive response measures were formulated.

Results  A total of 65 judgments were retrieved, and seven judgments were included. The main drugs causing cross allergy were antibiotics (penicillins, cephalosporins and sulfonamides). Seven cases of medical disputes, all of which were ruled by the court that the medical party had medical errors due to cross-allergies, and had to bear 30% to 80% of the compensation liability. The main reasons for the punishment were that the doctor did not pay enough attention to the patient's past history of allergy and chose unreasonable drugs.

Conclusion  Medical institutions can reduce the risk of cross-allergy by means of information technology, and play the role of pharmacists in prescription review and pharmaceutical care. Physicians should pay attention to the patient's past history, earnly inquire, strengthen medication education and monitoring, reduce the threat of adverse reactions to the patient's life safety and related drug disputes, and protect the legitimate rights and interests of both doctors and patients.

1.Hasdenteufel F, Luyasu S, Hougardy N, et al. Structure-activity relationships and drug allergy[J]. Curr Clin Pharmacol, 2012, 7(1): 15-27. DOI: 10.2174/157488412799218815.

2.Anovadiya AP, Barvaliya MJ, Patel TK, et al. Cross sensitivity between ciprofloxacin and levofloxacin for an immediate hypersensitivity reaction[J]. J Pharmacol Pharmacother, 2011, 2(3): 187-188. DOI: 10.4103/0976-500X.83285.

3.Li W, Zhu LL, Zhou Q. Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention[J]. Ther Clin Risk Manag, 2013, 9: 65-72. DOI: 10.2147/TCRM.S42013.

4.杨烁, 林平, 杨雅麟, 等. 从司法判决分析降低β内酰胺类药物过敏所致纠纷的策略[J]. 中国医院药学杂志, 2021, 41(13): 1341-1346. [Yang S, Lin P, Yang YL, et al. Analyzing the strategy to reduce β-lactam allergy disputes by judgment[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(13): 1341-1346.] DOI: 10.13286/j.1001-5213.2021.13.13.

5.Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis[J]. Otolaryngol Head Neck Surg, 2007, 136: 340-347. DOI: 10.1016/j.otohns.2006.10.007.

6.刘璇, 袁龙, 李为, 等. 641份具有磺酰胺结构的非抗菌药物说明书中交叉过敏警示标志分析及处方审核建议[J]. 药物流行病学杂志, 2023, 32(1): 25-29. [Liu X, Yuan L, Li W, et al. Analysis of cross allergy warning signs in 641 instructions for non-antibacterial drugs with sulfonamide structure and prescription audit suggestions[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(1): 25-29.] DOI: 10.19960/j.issn.1005-0698.202301004.

7.Thong BY. Update on the management of antibiotic allergy[J]. Allergy Asthma Immunol Res, 2010, 2(2): 77-86. DOI: 10.4168/aair.2010.2.2.77.

8.楼江, 王刚, 李晴宇, 等. 系统审核与人工审核相结合的处方前置审核模式对临床合理用药的影响[J]. 医药导报, 2020, 39(9): 1199-1202. [Lou J, Wang G, Li QY, et al. Impact of the combined mode of manual and system review in pre-prescription review system on rational drug use in the clinic[J]. Herald of Medicine, 2020, 39(9): 1199-1202.] DOI: 10.3870/j.issn.1004-0781.2020.09.004.

9.周良, 龚银华. 风险管理在药师审核干预门急诊处方中的应用与实践[J]. 2022, 19(6): 916-919. [Zhou L, Gong YH. The application and practice of risk management in phamacist's review and intervention of outpatient and emergecy prescriptions[J], Anti-Infection Pharmacy, 2022, 19(6): 916-919.] DOI: 10.13493/j.issn.1672-7878. 2022.06-039.

10.Macy E, Shu YH. The effect of penicillin allergy testing on future health care utilization: a matched cohort study[J]. J Allergy Clin Immunol Pract, 2017, 5(3): 705-710. DOI: 10.1016/j.jaip.2017.02.012.

11.原国家卫生和计划生育委员会, 国家中医药管理局, 原中国人民解放军总后勤部制药装备司. 抗生素临床应用原则(2015版)[S]. 2015.

12.Zagursky RJ, Pichichero ME. Cross-reactivity in β-lactam allergy[J]. Allergy Clin Immunol Pract, 2018, 6(1): 72-81.  DOI: 10.1016/j.jaip.2017.08.027.

13.中华人民共和国国家卫生健康委员会. β内酰胺类抗菌药物皮肤试验指导原则(2021年版)[J]. 中国实用乡村医生杂志, 2021, 28(5): 1-4. DOI: 10.3969/j.issn.1672-7185.2021.05.001.